<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/62341">
      <dc:title>A radiobiological study of the schemes with a low number of fractions in high-dose-rate brachytherapy as monotherapy for prostate cancer</dc:title>
      <dc:creator>Guirado Llorente, Damián</dc:creator>
      <dc:creator>Ruiz-Arrebola, Samuel</dc:creator>
      <dc:creator>Tornero-López, Ana M.</dc:creator>
      <dc:creator>de la Vega, Jose M.</dc:creator>
      <dc:creator>Prada, Pedro J.</dc:creator>
      <dc:creator>Lallena Rojo, Antonio Miguel</dc:creator>
      <dc:subject>HDR brachytherapy</dc:subject>
      <dc:subject>Prostate cancer</dc:subject>
      <dc:subject>Monotherapy</dc:subject>
      <dc:description>Purpose&#xd;
&#xd;
Schemes with high doses per fraction and small number of fractions are commonly used in high-dose-rate brachytherapy (HDR-BT) for prostate cancer. Our aim was to analyze the differences between published clinical results and the predictions of radiobiological models for absorbed dose required in a single fraction monotherapy HDR-BT.&#xd;
Material and methods&#xd;
&#xd;
Published HDR-BT clinical results for low- and intermediate-risk patients with prostate cancer were revised. For 13 clinical studies with 16 fractionation schedules between 1 and 9 fractions, a dose-response relation in terms of the biochemical control probability (BC) was established using Monte Carlo-based statistical methods.&#xd;
Results&#xd;
&#xd;
We obtained a value of α/β = 22.8 Gy (15.1-60.2 Gy) (95% CI) much larger than the values in the range 1.5-3.0 Gy that are usually considered to compare the results of different fractionation schemes in prostate cancer radiotherapy using doses per fraction below 6 Gy. The doses in a single fraction producing BC = 90% and 95% were 22.3 Gy (21.5-24.2 Gy) and 24.3 Gy (23.0-27.9 Gy), respectively.&#xd;
Conclusions&#xd;
&#xd;
The α/β obtained in our analysis of 22.8 Gy for a range of dose per fraction between 6 and 20.5 Gy was much greater than the one currently estimated for prostate cancer using low doses per fraction. This high value of α/β explains reasonably well the data available in the region of high doses per fraction considered.</dc:description>
      <dc:date>2020-06-03T08:11:14Z</dc:date>
      <dc:date>2020-06-03T08:11:14Z</dc:date>
      <dc:date>2020-04-18</dc:date>
      <dc:type>info:eu-repo/semantics/article</dc:type>
      <dc:identifier>Damián Guirado, Samuel Ruiz-Arrebola, Ana M. Tornero-López, et al. A radiobiological study of the schemes with a low number of fractions in high-dose-rate brachytherapy as monotherapy for prostate cancer. J Contemp Brachytherapy. 2020;12(2):193‐200. [doi:10.5114/jcb.2020.94492]</dc:identifier>
      <dc:identifier>http://hdl.handle.net/10481/62341</dc:identifier>
      <dc:identifier>10.5114/jcb.2020.94492</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by-nc-sa/3.0/es/</dc:rights>
      <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
      <dc:rights>Atribución-NoComercial-CompartirIgual 3.0 España</dc:rights>
      <dc:publisher>Termedia Publishing</dc:publisher>
   </ow:Publication>
</rdf:RDF>